Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2

Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase

(2017) Xianling Ning et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016)

(2017) Hidayat Hussain et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

The Warburg effect: 80 years on

(2016) Michelle Potter et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Cancer stem cell metabolism: a potential target for cancer therapy

(2016) Abhijeet Deshmukh et al.   Molecular Cancer

Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies

(2016) Kristofor A. Olson et al.   TRENDS IN BIOCHEMICAL SCIENCES

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents

(2015) Yuzheng Zhao et al.   Cell Metabolism

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

(2015) N. Theodosakis et al.   MOLECULAR CANCER THERAPEUTICS

Ferroxitosis: A cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma

(2015) Alexander J. Lakhter et al.   Oncotarget

Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway

(2014) Yongwei Wang et al.   BIOCHEMICAL PHARMACOLOGY

Sensitizing the Therapeutic Efficacy of Taxol with Shikonin in Human Breast Cancer Cells

(2014) Wenjuan Li et al.   PLoS One

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

How mitochondrial dysfunction affects zebrafish development and cardiovascular function: anin vivomodel for testing mitochondria-targeted drugs

(2013) Brígida R Pinho et al.   BRITISH JOURNAL OF PHARMACOLOGY

Targeting Oxidative Phosphorylation: Why, When, and How

(2013) Michael Pollak   CANCER CELL

PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress

(2013) Francisca Vazquez et al.   CANCER CELL

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

(2013) P. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Links between metabolism and cancer

(2012) C. V. Dang   GENES & DEVELOPMENT

PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells

(2012) Wenjuan Li et al.   MOLECULAR CARCINOGENESIS

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Identification and Functional Expression of the Mitochondrial Pyruvate Carrier

(2012) S. Herzig et al.   SCIENCE

A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans

(2012) D. K. Bricker et al.   SCIENCE

PKM2 and the Tricky Balance of Growth and Energy in Cancer

(2011) Andrew N. Macintyre et al.   MOLECULAR CELL

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

(2011) J Chen et al.   ONCOGENE

Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells

(2010) Sybille Mazurek   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Identification of small molecule inhibitors of pyruvate kinase M2

(2009) Matthew G. Vander Heiden et al.   BIOCHEMICAL PHARMACOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE